# 2026-23414: FDA Says Bromfed-DM Wasn't Pulled for Safety or Effectiveness

2026-23414, Determination That BROMFED-DM (Brompheniramine Maleate; Dextromethorphan Hydrobromide; Pseudoephedrine Hydrochloride) Syrup, 2 Milligrams/5 Milliliters; 10 Milligrams/5 Milliliters; 30 Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-11-18; PRIA reads it as touching household money (as of 2026-11-18).

- Canonical: https://policyrisk.com/federal-register/2026-23414
- As of: 2026-11-18
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23414
- Title: Determination That BROMFED-DM (Brompheniramine Maleate; Dextromethorphan Hydrobromide; Pseudoephedrine Hydrochloride) Syrup, 2 Milligrams/5 Milliliters; 10 Milligrams/5 Milliliters; 30 Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 74175
- Published: 2026-11-18
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-18

## In one line

FDA Says Bromfed-DM Wasn't Pulled for Safety or Effectiveness

## Summary

The FDA has confirmed that BROMFED-DM syrup, in all its strengths, wasn’t pulled from the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. If you rely on this cough and cold syrup, no worries—it’s staying available and safe for now!

## Abstract

The Food and Drug Administration (FDA, Agency, or we) has determined that BROMFED-DM (brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride) syrup, 2 milligrams (mg)/5 milliliters (mL); 10 mg/5 mL; 30 mg/5 mL, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generic Approvals May Continue: benefit, medium. FDA determined that BROMFED-DM syrup was not withdrawn for reasons of safety or effectiveness. As a result, FDA will not begin procedures to withdraw approval of approved abbreviated new drug applications (ANDAs) that refer to this product, and additional ANDAs referencing this listed drug may be a…
- Product Listed as Discontinued (Not for Safety): cost, low. FDA will continue to list BROMFED-DM syrup in the Orange Book’s “Discontinued Drug Product List,” which indicates the product was discontinued from marketing for reasons other than safety or effectiveness. The branded holder informed FDA of the discontinuation on January 8, 2026, and FDA found no e…

## Related documents

- [2026-23351](https://policyrisk.com/federal-register/2026-23351): Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, 2026-11-17
- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25

## Sources
- [2026-23414 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/18/2026-23414/determination-that-bromfed-dm-brompheniramine-maleate-dextromethorphan-hydrobromide-pseudoephedrine)
- [2026-23414 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-18/pdf/2026-23414.pdf)

## Related
- [Previous: 2026-23413, Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Applicatio…](https://policyrisk.com/federal-register/2026-23413)
- [Next: 2026-23416, Proposed Third-Party Risk Management Guidance; Extension of Comment Period](https://policyrisk.com/federal-register/2026-23416)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23414 (as of 2026-11-18).
